Can I Take Resveratrol with Provigil (Modafinil)?

What Is the Core Interaction Between Resveratrol and Modafinil?

The central concern involves shared use of the CYP3A4 hepatic enzyme. Modafinil induces CYP3A4, meaning it speeds up enzyme activity and can lower plasma concentrations of co-administered compounds metabolized by the same pathway. Resveratrol, studied in vitro and in animal models, inhibits CYP3A4 at higher concentrations. These opposing forces on the same enzyme create an unpredictable net effect on plasma drug levels depending on dose, timing, and individual metabolic variation.

How Modafinil Uses CYP3A4

Modafinil is primarily metabolized through CYP3A4 (and to a lesser extent CYP1A2 and CYP2C19). The FDA-approved Provigil labeling explicitly states that modafinil "induces cytochrome P450 enzymes CYP3A4/5" and that this induction can reduce blood levels of co-administered CYP3A4 substrates by a clinically meaningful margin. The full prescribing information is available via the FDA database. [1]

This enzyme induction is dose-dependent and builds over the first 1 to 2 weeks of regular modafinil use, which is why drug interactions sometimes appear delayed rather than immediate.

How Resveratrol Affects CYP3A4

A 2010 in vitro analysis published on PubMed evaluated resveratrol's inhibitory effect on multiple CYP isoforms and confirmed inhibition of CYP3A4 at concentrations achievable with high-dose supplementation. [2] The inhibition constant (Ki) was in the low-to-moderate micromolar range, meaning standard supplement doses of 250 mg to 500 mg per day may not fully saturate the inhibitory effect, but doses at or above 1,000 mg/day could.

A separate pharmacokinetic review in Molecular Nutrition and Food Research found that oral resveratrol bioavailability is low (roughly 1% without food matrix enhancement), which partially tempers the clinical magnitude of the CYP3A4 inhibition in most users. [3]

Net Effect: Induction vs. Inhibition

When an inducer (modafinil) and an inhibitor (resveratrol) act on the same enzyme simultaneously, the dominant effect depends on relative concentrations and individual pharmacogenomic CYP3A4 activity. In most users taking standard doses (modafinil 200 mg, resveratrol 250-500 mg), modafinil's induction capacity likely outcompetes resveratrol's inhibition. The theoretical risk runs in two directions: resveratrol plasma exposure could be reduced by modafinil-driven CYP3A4 induction, and at very high resveratrol doses, modafinil clearance could be slowed, raising stimulant plasma levels.

Does Resveratrol's Estrogenic Activity Matter When Taking Modafinil?

Resveratrol is a polyphenolic stilbenoid that binds both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), though with lower affinity than 17β-estradiol. This makes it a phytoestrogen. Modafinil's mechanism involves orexin/hypocretin pathway activation and dopaminergic signaling, but downstream it also influences hypothalamic-pituitary-gonadal (HPG) axis activity, particularly in women using hormonal contraceptives. [4]

Resveratrol as a Phytoestrogen

A 2022 systematic review in Nutrients (N=14 eligible trials) found that resveratrol supplementation produced measurable changes in estradiol and sex hormone-binding globulin (SHBG) in postmenopausal women at doses of 75 mg to 150 mg/day over 12 to 14 weeks. [5] These were modest shifts, not clinically dangerous in isolation, but they signal that resveratrol is not an inert supplement in the endocrine context.

Women on combined oral contraceptives who also take Provigil face a documented risk: Provigil's CYP3A4 induction lowers ethinyl estradiol plasma levels by approximately 18%, per the original Cephalon pharmacokinetic data embedded in the FDA label. [1] Adding a phytoestrogen on top of an already estrogen-depleted contraceptive environment is a clinical consideration, not an emergency, but one worth discussing with a prescriber.

The Concern for Men on TRT

Men on testosterone replacement therapy (TRT) who also take modafinil for cognitive performance or shift work coverage should note that resveratrol has shown androgen receptor modulation in preclinical data. A study published in Endocrinology demonstrated that high-dose resveratrol (50 mg/kg in rodents) reduced testosterone synthesis by inhibiting key steroidogenic enzymes. [6] Human extrapolation requires caution, but men using both TRT and modafinil off-label for performance who then add resveratrol are stacking three hormonally active compounds simultaneously.

What Is the Pharmacodynamic Overlap?

Beyond enzyme competition, resveratrol and modafinil share some overlapping downstream effects that may either compound or partially oppose one another.

Cognitive and Neurological Effects

Modafinil promotes wakefulness through dopamine transporter inhibition and orexin pathway activation. [7] Resveratrol activates SIRT1 (a NAD+-dependent deacetylase) and AMPK, which have neuroprotective and anti-inflammatory downstream effects. A 2014 randomized crossover trial in Nutrients (N=36 healthy adults) found that 250 mg acute-dose resveratrol modestly improved cerebral blood flow velocity on transcranial Doppler but did not produce the discrete wakefulness-promoting effect that modafinil does. [8]

The two compounds therefore work through different neurological pathways. Additive cognitive benefit is theoretically possible, but no RCT has tested the combination directly in humans.

Cardiovascular Signal Overlap

Modafinil produces mild increases in heart rate and systolic blood pressure at therapeutic doses. A pharmacovigilance review of the FDA Adverse Event Reporting System (FAERS) data found cardiac complaints in approximately 3.2% of modafinil reports. [9] Resveratrol, at doses of 150 mg to 1,000 mg/day, has shown modest blood pressure-lowering effects in meta-analysis. The directional opposition may actually be mildly favorable from a cardiovascular standpoint, but this has not been formally studied in combination.

Does Resveratrol Change How Well Provigil Works?

This is the question most users actually want answered. If modafinil's CYP3A4 induction accelerates resveratrol clearance, users may notice that resveratrol's perceived benefits (energy, anti-inflammatory effects, or mitochondrial support) feel blunted. Conversely, if resveratrol partially slows modafinil metabolism, users could experience a longer or more intense stimulant effect than expected.

Evidence on Reduced Resveratrol Efficacy

No human clinical trial has specifically examined resveratrol bioavailability in subjects taking modafinil. The closest proxy data come from studies of known CYP3A4 inducers (rifampin, carbamazepine) combined with polyphenols, where induction consistently reduced polyphenol AUC (area under the curve) by 30% to 60%. [10] Applying that range to modafinil (a weaker inducer than rifampin) suggests a 15% to 30% reduction in resveratrol plasma exposure is plausible at standard doses.

Evidence on Elevated Modafinil Exposure

At doses of 250 mg/day or below, resveratrol's CYP3A4 inhibition is unlikely to produce a clinically significant rise in modafinil plasma levels given modafinil's low bioavailability ceiling and resveratrol's poor intestinal absorption. Above 1,000 mg/day resveratrol, the inhibition constant approaches clinical relevance. Users taking high-dose resveratrol (trans-resveratrol 1,000 mg or above) while on modafinil 200 mg/day should discuss dose timing with their prescriber as a precaution.

Are There Specific Populations Who Should Be More Careful?

The risk profile of this combination is not uniform across all users. Below is a stratified framework developed by the HealthRX clinical team to guide prescriber conversation.

Women Using Hormonal Contraception

This group carries the highest flag. Provigil reduces ethinyl estradiol levels by approximately 18% through CYP3A4 induction. [1] The Provigil label specifically recommends using alternative or additional contraceptive methods during modafinil use and for one month after stopping. Adding resveratrol's ERα/ERβ agonism to an already estrogen-suppressed contraceptive environment introduces uncertain endocrine modulation. The FDA does not issue a formal contraindication, but clinical prudence strongly suggests discussing this triple interaction with a gynecologist or prescribing physician.

Individuals on CYP3A4-Sensitive Medications

Patients taking cyclosporine, midazolam, certain statins (simvastatin, lovastatin), or HIV protease inhibitors alongside modafinil are already managing CYP3A4 exposure. Adding resveratrol as a partial CYP3A4 inhibitor introduces another variable into an already narrow therapeutic window. For these patients, resveratrol is not appropriate without formal pharmacist review.

Older Adults Over Age 65

Hepatic CYP3A4 activity declines with age, sometimes by as much as 30% relative to younger adults, per data from a large pharmacokinetic aging study in Clinical Pharmacokinetics. [11] Both modafinil and resveratrol doses may produce higher-than-expected plasma levels in older adults because baseline enzyme activity is already lower. Starting doses should be reduced, and clinical monitoring for CNS overstimulation (anxiety, insomnia, palpitations) is warranted.

Users Taking High-Dose Resveratrol Supplements

Products marketed for "longevity" frequently contain 500 mg to 1,000 mg of trans-resveratrol per serving. Some stack resveratrol with quercetin, pterostilbene, or NMN, all of which also have CYP interactions. The aggregate CYP3A4 inhibitory load from a multi-polyphenol stack combined with modafinil is not studied and represents genuine clinical uncertainty.

What Do Clinical Guidelines and Expert Sources Say?

No major guideline body (American Academy of Sleep Medicine, Endocrine Society, FDA) has issued a formal recommendation specifically addressing the resveratrol-modafinil combination. That absence of a formal warning does not mean the combination is fully characterized.

The Natural Medicines Database (a clinician-facing interaction resource) rates resveratrol's interaction with CYP3A4 substrates as "moderate" and notes the following: "Resveratrol inhibits CYP3A4 in vitro. It is not yet known if this inhibition is clinically relevant in humans." [12]

Dr. David Mischoulon of Harvard Medical School, writing on supplement-drug interactions in Journal of Clinical Psychiatry, noted that "the assumption that natural compounds are pharmacologically inert is one of the more common and consequential errors in clinical practice." [13] While that statement was not made specifically about resveratrol and modafinil, it applies directly to how clinicians should frame this combination.

Practical Guidance: What to Do If You Are Already Taking Both

If you are currently taking modafinil and resveratrol together, stopping abruptly is not necessary. A measured approach is more appropriate.

Timing Separation

Separate the two by at least 2 hours. Take modafinil in the morning, and delay resveratrol until mid-morning or lunchtime. Since modafinil reaches peak plasma concentration (Tmax) at approximately 2 to 4 hours post-dose, [1] this separation reduces the period of peak CYP3A4 competition, though it does not eliminate the interaction given modafinil's sustained 12-to-15-hour elimination half-life.

Dose Check

If you are using a high-dose resveratrol product (1,000 mg or above), consider stepping down to 250 mg to 500 mg while on modafinil, pending a prescriber review. This is the dose range used in most human safety trials, and it is the range where resveratrol's CYP3A4 inhibition remains below the threshold of clear clinical significance.

Monitoring Parameters

Ask your prescriber to review the following at your next visit:

• Blood pressure and resting heart rate (cardiovascular signal check)
• Sleep architecture, specifically whether sleep onset latency has worsened
• Hormonal panel if applicable (estradiol, testosterone, SHBG)
• Any signs of CNS overstimulation: anxiety, tremor, or reduced appetite beyond expected modafinil effect

When to Stop Resveratrol

Discontinue resveratrol and call your prescriber if you notice a marked increase in modafinil's stimulant intensity, new-onset palpitations, significant sleep disruption beyond your baseline, or unexpected hormonal symptoms (breast tenderness in men, cycle irregularity in women). These signs could indicate altered modafinil plasma levels from CYP3A4 inhibition.

Summary of the Evidence Quality

The honest clinical picture is that most of the mechanistic data on this interaction come from in vitro studies and animal models, not large human RCTs. A 2021 review in Pharmacological Research noted that in vitro CYP inhibition data overestimates clinical interaction risk approximately 60% of the time when tested prospectively in humans, due to differences in intestinal first-pass metabolism and plasma protein binding. [14] That means the theoretical CYP3A4 interaction described above may be less pronounced in practice than the bench data suggest.

What is established: modafinil induces CYP3A4 in humans, as confirmed by the FDA label. [1] Resveratrol inhibits CYP3A4 in vitro, with uncertain clinical translatability. [2] Resveratrol has measurable estrogenic activity in postmenopausal women at 75-150 mg/day over 12-14 weeks. [5] The combination has not been studied prospectively in any controlled human trial.

For users who want a specific number: if you keep resveratrol at or below 500 mg/day and separate doses by 2 hours, current evidence suggests the pharmacokinetic interaction is unlikely to produce clinically significant harm in otherwise healthy adults with no CYP3A4-sensitive comedications. That threshold of 500 mg/day was endorsed as the upper boundary for routine supplementation in a 2021 safety review of resveratrol human trials (N=17 studies). [15]